Great Britain vs Northern Ireland
This page is based on the UK Medical Devices Regulations 2002 (SI 2002/618) as it applies in Great Britain, and EU MDR 2017/745 and EU IVDR 2017/746 as they apply in Northern Ireland under the Windsor Framework (agreed March 2023, implementing arrangements under the Protocol on Ireland/Northern Ireland to the UK–EU Withdrawal Agreement).
This site provides general information only and does not constitute legal or regulatory advice. The regulatory position for Northern Ireland is subject to ongoing UK–EU agreements and may change. Always verify against current MHRA and DHSC guidance before making regulatory decisions.
Why there are two regimes within the UK
When the United Kingdom left the European Union, Great Britain (England, Scotland, and Wales) became a separate regulatory jurisdiction. Northern Ireland's situation is unique: to preserve the frictionless flow of goods across the Ireland/Northern Ireland land border, Northern Ireland remains aligned with EU single market rules for goods — including medical devices.
The result is that the United Kingdom, as a single political entity, operates two distinct medical device regulatory regimes simultaneously:
| Territory | Applicable framework | Marking required | Regulator |
|---|---|---|---|
| Great Britain (England, Scotland, Wales) | UK MDR 2002 (as amended) | UKCA | MHRA |
| Northern Ireland | EU MDR 2017/745 / EU IVDR 2017/746 | CE | MHRA (acting as a Member State CA) + EU oversight |
Great Britain — the UK MDR 2002 regime
In Great Britain, devices must comply with the UK Medical Devices Regulations 2002 (SI 2002/618) as amended by the Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 and subsequent statutory instruments.
What is required for the GB market
- UKCA marking — the UK conformity assessed mark, which replaced CE marking for the GB market from 1 January 2021.
- MHRA registration — manufacturers, UK Responsible Persons (UKRPs), and authorised representatives must register with MHRA via the Submissions portal.
- UK Approved Body (UKAB) involvement — for Class IIa, IIb, III, and AIMD devices, and for Annex II List A and List B IVDs.
- UK declaration of conformity — the manufacturer's declaration that the device meets the Essential Requirements of UK MDR 2002.
CE marking transitional acceptance in GB
A critical and evolving aspect of GB market access is the transitional acceptance of CE marking:
| Period | Position |
|---|---|
| 1 Jan 2021 – 30 Jun 2023 | CE marking accepted in GB |
| 1 Jul 2023 – 30 Jun 2030 (current) | CE marking accepted in GB for devices CE-marked under EU MDR or EU IVDR before 30 Jun 2030 |
| From 1 Jul 2030 | UKCA marking required; CE marking no longer sufficient for the GB market |
The Government extended CE marking acceptance until 30 June 2030 in a June 2023 announcement. This means manufacturers with valid EU MDR/IVDR CE certification do not need to immediately obtain UKCA marking for GB. However, it is strongly advisable to begin planning UKCA transition well ahead of the 2030 deadline, given UKAB capacity constraints.
Northern Ireland — the EU MDR / IVDR regime
Under the Windsor Framework (March 2023), Northern Ireland continues to follow EU single market rules for goods. For medical devices, this means:
- EU MDR 2017/745 applies to general medical devices placed on the NI market
- EU IVDR 2017/746 applies to IVD medical devices placed on the NI market
- CE marking is required for the NI market
- EU Notified Bodies must be used for devices requiring third-party conformity assessment for the NI market
- EUDAMED registration requirements apply
MHRA acts as the Competent Authority for Northern Ireland in its capacity as a national authority, but operates under EU rules. Devices with safety issues in NI may trigger EU-wide actions.
What changed with the Windsor Framework (2023)
The Windsor Framework replaced the earlier Northern Ireland Protocol in March 2023. Key changes for medical devices:
- "Green Lane" for GB-origin goods — goods moving from Great Britain to Northern Ireland for end use and sale in Northern Ireland can use a simplified customs process, but must still comply with EU rules for medical devices.
- Stormont Brake — Northern Ireland's Assembly gained a mechanism to object to new EU rules being applied in NI, subject to UK–EU agreement. This has limited immediate practical impact on medical device regulation.
- Ongoing regulatory alignment — The fundamental requirement that NI aligns with EU MDR/IVDR rules remains unchanged.
UKCA, CE, and the UKNI indication
Three marks are relevant to manufacturers operating across the UK:
UKCA mark
- Required for the GB market (England, Scotland, Wales)
- Applied when conformity has been assessed under UK MDR 2002
- The UKCA mark is not accepted in the EU or Northern Ireland
CE mark
- Required for the EU market and the Northern Ireland market
- Applied when conformity has been assessed under EU MDR 2017/745 or EU IVDR 2017/746
- CE marking is accepted in GB under transitional arrangements (until 30 June 2030)
UKNI indication
- A device carrying the UKNI indication alongside the CE mark has been assessed by a UK Approved Body for the Northern Ireland market
- Required when a device is assessed by a UKAB (rather than an EU Notified Body) but needs to be placed on the NI market
- Products with UKNI may not be placed on the EU market — only in the UK (including NI)
| Mark | GB market | NI market | EU market |
|---|---|---|---|
| UKCA only | ✅ | ❌ | ❌ |
| CE only | ✅ (until 30 Jun 2030) | ✅ | ✅ |
| UKCA + UKNI | ✅ | ✅ | ❌ |
| CE + UKNI | ✅ | ✅ | ❌ |
Practical implications for manufacturers
Scenario 1: Manufacturer selling only in Great Britain
- Comply with UK MDR 2002
- Obtain UKCA marking (or rely on CE marking transitional acceptance until 2030)
- Register with MHRA
- Appoint a UKRP if not established in the UK
Scenario 2: Manufacturer selling in both GB and NI (all-UK)
- Must satisfy both frameworks
- For most manufacturers, the practical approach is to maintain EU MDR/IVDR CE certification (satisfying NI) and rely on the CE marking transitional acceptance for GB until 2030
- From 2030 onward: maintain both CE (for NI) and UKCA (for GB)
- Vigilance reporting goes to both MHRA (GB events) and MHRA in its NI/EU CA capacity
Scenario 3: Manufacturer selling in UK and EU
- Maintain CE marking via EU Notified Body for EU + NI market
- Rely on CE marking transitional acceptance for GB (until 2030) or obtain UKCA marking separately
- One UKRP required for GB; EU Authorised Representative (EU REP) required for EU
Scenario 4: Non-UK, non-EU manufacturer entering the GB market
- Appoint a UKRP established in Great Britain
- UKRP registers the manufacturer and devices with MHRA
- UKRP's details appear on the device label (or on packaging)
Registration: MHRA vs EUDAMED
| Requirement | Great Britain | Northern Ireland |
|---|---|---|
| Register with | MHRA Submissions portal | EUDAMED (EU) |
| Who registers | Manufacturer or UKRP | Manufacturer or EU Authorised Representative |
| Timing | Before placing device on GB market | Before placing device on EU/NI market |
| Scope | Device, manufacturer, UKRP | Device, manufacturer, EU REP, certificates |
Vigilance reporting: MHRA vs Member State CAs
Adverse events and FSCAs must be reported to the regulator for the market where the event occurs:
- Events in Great Britain → Report to MHRA (as GB regulator) via the MHRA Yellow Card scheme or MHRA Submissions
- Events in Northern Ireland → Report to MHRA (acting in its EU CA capacity for NI) — MHRA routes NI reports into EU vigilance processes
- Events affecting both GB and NI → A single report to MHRA covers both, but the downstream handling differs
Future outlook
The divergence between GB and NI medical device regulation is expected to continue for the foreseeable future. Key developments to watch:
- MHRA's regulatory reform programme — The Medical Devices Act 2021 enables significant reform of UK MDR 2002. MHRA has consulted on a new framework more closely resembling EU MDR/IVDR in structure. If adopted, this could reduce — but not eliminate — the GB/NI divergence.
- UKCA rollout and UKAB capacity — The ability of UK Approved Bodies to absorb demand as CE marking transitional acceptance ends in 2030 is a significant industry concern.
- Windsor Framework evolution — The UK–EU relationship continues to evolve. Any mutual recognition agreement on medical devices would fundamentally change the current landscape.
Related pages
- What is a medical device? — the GB definition under UK MDR 2002
- Who needs to comply? — including UKRP obligations
- UKCA marking requirements
- Northern Ireland & Windsor Framework
- Post-Brexit transition timeline
- UK Approved Bodies
Official references
| Reference | Description |
|---|---|
| UK MDR 2002 (SI 2002/618) | Primary GB medical device regulation |
| SI 2019/791 | Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 |
| EU MDR 2017/745 | Applies in Northern Ireland |
| EU IVDR 2017/746 | Applies in Northern Ireland |
| Windsor Framework (March 2023) | UK–EU agreement governing NI's continued EU alignment |
| MHRA guidance: Regulating medical devices in the UK | Current MHRA position on GB vs NI |
| DHSC: UKCA marking | Government policy on UKCA transitional arrangements |